Truist analyst Richard Newitter lowered the firm’s price target on Axonics to $73 from $82 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in MedTech space. The intra-quarter feedback, including the firm’s Q1 hospital utilization survey leaves Truist bullish on underlying Q1 utilization trends for the sector and confident that MedTech companies will likely deliver in-line or better top-line results with modestly raised organic 2023 revenue outlooks, though the sector’s rally and raised expectations in recent weeks is also already likely reflected to some degree in valuations, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX:
- Axonics initiated with a Buy at Mizuho
- Axonics management to meet with Piper Sandler
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Needham upgrades Axonics to Buy on conservative guidance, attractive valuation
- Axonics upgraded to Buy from Hold at Needham
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue